Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: a systematic review and meta-analysis

Advanced breast cancer is encountered in around 5-10% of patients with primary breast cancers [1], and another 10% of the patients develop distant recurrence within 5 years after primary disease and treatment [2,3]. Once breast cancer has metastasized to distant locations, it is generally considered amenable to palliative rather than curative care. Therefore, the goals of treatment at this later stage are focused on delaying the progression of the metastatic disease, relief of cancer-related symptoms and maintaining quality of life [1].

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2m26KO9
via IFTTT